| Subgroup | Study | Case (/) | Heterogeneity | Effect size | LCVP | Control | | | RR(95% CI) | |
| Diagnosis | | | | | | | | Chest infection | [14, 18–20, 23, 25] | 20/283 | 37/327 | 0% | 0.96 | 0.56 (0.35, 0.90) | 0.02 | Pleural effusion | [14, 18–20, 23, 25] | 41/283 | 57/327 | 43% | 0.12 | 0.72 (0.51, 1.02) | 0.06 | Wound infection | [14, 23] | 5/120 | 7/111 | 0% | 0.75 | 0.64 (0.21, 1.93) | 0.43 | Ascites | [14, 18, 23] | 12/140 | 22/169 | 0% | 0.81 | 0.56 (0.29, 1.08) | 0.08 | Heart disorder | [18, 20] | 1/87 | 2/141 | 0% | 0.40 | 1.36 (0.19, 9.67) | 0.76 | Bile leakage | [18, 20] | 2/80 | 2/111 | 0% | 0.75 | 1.41 (0.22, 9.23) | 0.72 | Bleeding | [18, 20] | 0/80 | 3/111 | 0% | 0.45 | 0.35 (0.05, 2.67) | 0.31 | Hepatic insufficiency | [18, 20] | 3/80 | 5/111 | 0% | 0.49 | 0.90 (0.21, 3.85) | 0.88 | Sepsis | [18, 20] | 3/103 | 4/101 | 0% | 0.33 | 0.77 (0.20, 3.02) | 0.71 | Methods | | | | | | | | IVCC versus control | [14, 18, 20, 23] | 52/207 | 69/252 | 0% | 0.50 | 0.83 (0.62, 1.11) | 0.2 | IAC versus control | [15, 19, 25] | 47/101 | 68/100 | 0% | 0.70 | 0.68 (0.55, 0.86) | 0.009 | Total | | | | | | | | LCVP versus control | [14, 15, 18–20, 23, 25] | 99/308 | 137/352 | 0% | 0.71 | 0.75 (0.63, 0.91) | 0.003 |
|
|